Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention 　- A Meta-Analysis of 12 Randomized Trials.

CONCLUSIONS: In secondary prevention patients, the relative benefits of high-dose statin, ezetimibe-statin, and PCSK9 inhibitor-statin treatments were varied and decreased gradually, of which high-dose statin was significantly superior to PCSK9 inhibitor-statin for improving MACE and revascularization per 1 mmol/L reduction of LDL-C. PMID: 31006730 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31006730?dopt=Abstract

Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Wang S, Xiu J, Liao W, Liao Y, Bin J Tags: Circ J Source Type: research

Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention - A Meta-Analysis of 12 Randomized Trials.

Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention 　- A Meta-Analysis of 12 Randomized Trials.